{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:55Z","timestamp":1790810095900,"version":"4.1.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/bor.0000000000000069","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T14:00:07Z","timestamp":1400076007000},"page":"361-370","source":"Crossref","is-referenced-by-count":80,"title":["The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis"],"prefix":"10.1097","volume":"26","author":[{"given":"Nataliya","family":"Yeremenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline E.","family":"Paramarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis.","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the antitumor necrosis factor alpha monoclonal antibody infliximab.","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","article-title":"Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.","volume":"59","author":"Van den Bosch","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/annrheumdis-2013-203327","article-title":"Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis.","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial.","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nm.3268","article-title":"How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases.","volume":"19","author":"Baeten","year":"2013","journal-title":"Nat Med"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1074\/jbc.M700499200","article-title":"Identification of an interleukin 17F17A heterodimer in activated human CD4 T cells.","volume":"282","author":"Wright","year":"2007","journal-title":"J Biol Chem"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cyto.2007.11.013","article-title":"Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy.","volume":"41","author":"Shen","year":"2008","journal-title":"Cytokine"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.immuni.2008.11.005","article-title":"Late developmental plasticity in the T helper 17 lineage.","volume":"30","author":"Lee","year":"2009","journal-title":"Immunity"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10957","article-title":"Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta.","volume":"484","author":"Zielinski","year":"2012","journal-title":"Nature"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/ncomms4199","article-title":"TNF-alpha blockade induces IL-10 expression in human CD4 T cells.","volume":"5","author":"Evans","year":"2014","journal-title":"Nat Commun"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.4049\/jimmunol.0900732","article-title":"Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells.","volume":"182","author":"Awasthi","year":"2009","journal-title":"J Immunol"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.","volume":"39","author":"Burton","year":"2007","journal-title":"Nat Genet"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"e1001195","DOI":"10.1371\/journal.pgen.1001195","article-title":"Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohns disease.","volume":"6","author":"Danoy","year":"2010","journal-title":"PLoS Genet"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/ng.873","article-title":"Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.","volume":"43","author":"Evans","year":"2011","journal-title":"Nat Genet"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.","volume":"45","author":"Cortes","year":"2013","journal-title":"Nat Genet"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/gene.2010.17","article-title":"Elucidating the chromosome 9 association with AS: CARD9 is a candidate gene.","volume":"11","author":"Pointon","year":"2010","journal-title":"Genes Immun"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1476-5381.2010.00647.x","article-title":"A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models.","volume":"160","author":"Chen","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R23-2-20210128","first-page":"2159","article-title":"Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles.","volume":"29","author":"Gu","year":"2002","journal-title":"J Rheumatol"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/03009740802213310","article-title":"Upregulation of 78-kDa glucose-regulated protein in macrophages in peripheral joints of active ankylosing spondylitis.","volume":"37","author":"Dong","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/art.30593","article-title":"Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response.","volume":"63","author":"Zeng","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/art.10605","article-title":"Cell-surface expression and immune receptor recognition of HLA-B27 homodimers.","volume":"46","author":"Kollnberger","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2 and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis.","volume":"186","author":"Bowness","year":"2011","journal-title":"J Immunol"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis.","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"e31000","DOI":"10.1371\/journal.pone.0031000","article-title":"Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis.","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gammadelta T cells in patients with active ankylosing spondylitis.","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3899\/jrheum.120208","article-title":"Cytokine secretion by pathogen recognition receptor-stimulated dendritic cells in rheumatoid arthritis and ankylosing spondylitis.","volume":"39","author":"Prevosto","year":"2012","journal-title":"J Rheumatol"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17() cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response.","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.37937","article-title":"In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis.","volume":"65","author":"Appel","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis.","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/art.24763","article-title":"HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats.","volume":"60","author":"DeLay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.33321","article-title":"Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats.","volume":"64","author":"Glatigny","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/s10165-009-0166-0","article-title":"Ankylosing enthesitis associated with up-regulated IFN-gamma and IL-17 production in (BXSB x NZB) F(1) male mice: a new mouse model.","volume":"19","author":"Abe","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat CD3CD4-CD8- entheseal resident T cells.","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"R41-2-20210128","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"e17160","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans.","volume":"6","author":"Di","year":"2011","journal-title":"PLoS One"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1073\/pnas.1017854108","article-title":"Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4 and CD8 human T-cell functional responses.","volume":"108","author":"Sarin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1002\/art.34561","article-title":"Expression of HLA-B27 causes loss of migratory dendritic cells in a rat model of spondylarthritis.","volume":"64","author":"Utriainen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R46-2-20210128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrg3502","article-title":"Genetic insights into common pathways and complex relationships among immune-mediated diseases.","volume":"14","author":"Parkes","year":"2013","journal-title":"Nat Rev Genet"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials.","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R48-2-20210128","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2013-204170","article-title":"No evidence for a critical role of the unfolded protein response in synovium and blood of patients with ankylosing spondylitis.","volume":"73","author":"Neerinckx","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/ard.2009.107649","article-title":"Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis.","volume":"69","author":"Melis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R50-2-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10067-008-1011-0","article-title":"Serum and synovial fluid levels of p40IL1223 in spondyloarthropathy patients.","volume":"28","author":"Wendling","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R51-2-20210128","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4049\/jimmunol.1003986","article-title":"IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass.","volume":"187","author":"Adamopoulos","year":"2011","journal-title":"J Immunol"},{"key":"R52-2-20210128","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.20120707","article-title":"Tristetraprolin regulation of interleukin 23 mRNA stability prevents a spontaneous inflammatory disease.","volume":"210","author":"Molle","year":"2013","journal-title":"J Exp Med"},{"key":"R53-2-20210128","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R54-2-20210128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"R55-2-20210128","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Antiinterleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"R56-2-20210128","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an antiinterleukin-17-receptor antibody for psoriasis.","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"R57-2-20210128","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with moderate-to-severe Crohns disease.","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"R58-2-20210128","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohns disease.","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"R59-2-20210128","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial.","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"R60-2-20210128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 1223 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"R61-2-20210128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"R63-2-20210128","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R64-2-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R65-2-20210128","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Antiinterleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"issue":"Suppl3","key":"R66-2-20210128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/annrheumdis-2013-eular.308","article-title":"Efficacy of brodalumab, an anti-IL-17R antibody, in subjects with psoriatic arthritis abstract.","volume":"72","author":"Mease","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"R67-2-20210128","first-page":"S1080","article-title":"Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study abstract.","volume":"64","author":"Ritchlin","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T22:34:11Z","timestamp":1746225251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201407000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000069","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}